Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million
05/08/2026 11:31
BRIEF-Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million Aug 05 (Reuters) - Recursion Pharmaceuticals Q2 pretax profit USD -131.006 million.
- Q2 operating income USD -134.968 million
- Q2 net income USD -131.005 million
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million